Dr Sartor interviews dr Taylor who is the lead researcher on copper isotopes to be used for precision medicine for prostate cancer and not only. The first patient with mCRPC treated with 2 infusions at therapeutic dose, complete remission...ok, luck, but still, I like it!
But their enthusiasm is higher than mine, I hope it's not marketing: "But prostate is our major area with bisPSMA. And that's Copper-67 bisPSMA. We're excited about that because of the early data, even in late-stage disease and having, you saw the complete response in the first patient we ever treated twice at what we thought was a therapeutic dose, was amazing. That wasn't a combination. That was after everything. And to have that sort of dramatic response."